Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis

myVectraTM Enables Secure Access to Vectra® DA Test Results SOUTH SAN FRANCISCO, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,...
May 06, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Present Three New Studies at the AUA Annual Meeting

SALT LAKE CITY, May 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies...
May 03, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results

Total Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and Updates Fiscal Year 2016 Financial Guidance SALT LAKE CITY, May 03,...
May 02, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the Bank of America Health Care Conference

SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that R. Bryan Riggsbee, chief financial officer, Myriad Genetics, is scheduled to present at...
April 22, 2016 15:30 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3

SALT LAKE CITY, April 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with...
April 14, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting

SALT LAKE CITY, April 14, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company and its...
March 30, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing for Breast Cancer Patients

SALT LAKE CITY, March 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, working in collaboration with...
March 21, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing

SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program...
March 18, 2016 07:05 ET | Source: Myriad Genetics, Inc.

The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer

SALT LAKE CITY, March 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two important...
March 15, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test

SALT LAKE CITY, March 15, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced the results from the second...